Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H7N2O5.Na |
| Molecular Weight | 330.2269 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OC1=CC(=NC2=C1C3=NC4=C(OC3=CC2=O)C=CC=C4)C([O-])=O
InChI
InChIKey=HDQXPMXHXZNPKE-UHFFFAOYSA-M
InChI=1S/C16H8N2O5.Na/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12;/h1-6H,(H,18,19)(H,21,22);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H7N2O5 |
| Molecular Weight | 307.2372 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/21850160Curator's Comment: description was created based on several sources, including, http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02021053&Seq=007&Type=9
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160
Curator's Comment: description was created based on several sources, including, http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02021053&Seq=007&Type=9
Pirenoxine is an anti-cataract agent which is used in many asian countries under the name Catalin. Although its efficacy is not proved scientifically, the drug may play an important role in cataract prevention. It is supposed that the anti-cataract effect of pirenoxine results from inhibition of sulfhydryl combination of quinoid substances with lens proteins and the inhibition leads to the maintenance of lens transparency.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0036438 Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | CATALIN Approved UseEarly stage of senile cataract. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Efficacy of catalin eyed drops in age-related cataract agents]. | 2010-07-22 |
|
| Why are physicians not persuaded by scientific evidence? A grounded theory interview study. | 2006-07-27 |
|
| Pirenoxine prevents oxidative effects of argon fluoride excimer laser irradiation in rabbit corneas: biochemical, histological and cytofluorimetric evaluations. | 2005-01-14 |
|
| Contact dermatitis due to pirfenoxone. | 2004-06 |
|
| [Evaluation of effectiveness of Catalin eyedrops in patients with presenile and senile cataract]. | 2004 |
|
| Antioxidant protection in cultured corneal cells and whole corneas submitted to UV-B exposure. | 2003-10-15 |
Patents
Sample Use Guides
Dissolve the granules (0.75 mg) in 15 ml of the vehicle just before use and instill 1-2 drops of the
solution, 3-5 times a day
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160
Pirenoxine (1,000 uM) decreased UVC-induced turbidity formation compared to controls after 4 h of UVC exposure. The absolute gamma-crystallin turbidity induced by 4 h of UVC exposure was ameliorated in the presence of catalin equivalent to 1-100 uM of the drug in a concentration-dependent manner. Pirenoxine at 0.03, 0.1, and 0.3 uM significantly delayed 10 mM selenite- and calcium-induced turbidity formation compared to controls on days 0-4.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:20:56 GMT 2025
by
admin
on
Mon Mar 31 19:20:56 GMT 2025
|
| Record UNII |
95JU7URF64
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23695982
Created by
admin on Mon Mar 31 19:20:56 GMT 2025 , Edited by admin on Mon Mar 31 19:20:56 GMT 2025
|
PRIMARY | |||
|
DTXSID1046637
Created by
admin on Mon Mar 31 19:20:56 GMT 2025 , Edited by admin on Mon Mar 31 19:20:56 GMT 2025
|
PRIMARY | |||
|
257-181-6
Created by
admin on Mon Mar 31 19:20:56 GMT 2025 , Edited by admin on Mon Mar 31 19:20:56 GMT 2025
|
PRIMARY | |||
|
SUB20995
Created by
admin on Mon Mar 31 19:20:56 GMT 2025 , Edited by admin on Mon Mar 31 19:20:56 GMT 2025
|
PRIMARY | |||
|
100000087311
Created by
admin on Mon Mar 31 19:20:56 GMT 2025 , Edited by admin on Mon Mar 31 19:20:56 GMT 2025
|
PRIMARY | |||
|
m8873
Created by
admin on Mon Mar 31 19:20:56 GMT 2025 , Edited by admin on Mon Mar 31 19:20:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
51410-30-1
Created by
admin on Mon Mar 31 19:20:56 GMT 2025 , Edited by admin on Mon Mar 31 19:20:56 GMT 2025
|
PRIMARY | |||
|
95JU7URF64
Created by
admin on Mon Mar 31 19:20:56 GMT 2025 , Edited by admin on Mon Mar 31 19:20:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |